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Abstract
Background: Diabetes is becoming one of the most common chronic diseases, and ulcers are its
most serious complication. Beginning with neuropathy, the subsequent foot wounds frequently lead
to lower extremity amputation, even in the absence of critical limb ischemia. In recent years, some
researchers have studied external shock wave therapy (ESWT) as a new approach to soft tissue
wound healing. The rationale of this study was to evaluate if ESWT is effective in the management
of neuropathic diabetic foot ulcers.
Methods: We designed a randomized, prospective, controlled study in which we recruited 30
patients affected by neuropathic diabetic foot ulcers and then divided them into two groups based
on different management strategies. One group was treated with standard care and shock wave
therapy. The other group was treated with only standard care. The healing of the ulcers was
evaluated over 20 weeks by the rate of re-epithelization.
Results: After 20 weeks of treatment, 53.33% of the ESWT-treated patients had complete wound
closure compared with 33.33% of the control patients, and the healing times were 60.8 and 82.2
days, respectively (p < 0.001). Significant differences in the index of the re-epithelization were
observed between the two groups, with values of 2.97 mm2/die in the ESWT-group and 1.30 mm2/
die in the control group (p < 0.001).
Conclusion: Therefore, ESWT may be a useful adjunct in the management of diabetic foot
ulceration.
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Background
The rapid rise in the incidence of diabetes is an alarming
concern to health care professionals, largely because of
the serious associated complications. Recent data from
the Centers for Disease Control and Prevention approxi-
mate that 20.8 million people, roughly 7% of the United
States' population, have diabetes [1]. In 2005 alone, 1.5
million new cases of diabetes were diagnosed in people
aged 20 years or older [1]. Diabetes mellitus is a disease
known for its multifaceted complications, and foot ulcer-
ation, which often results in lower extremity amputations,
is one of the most common complications associated with
the disease [2-5]. The prevalence of foot ulcers ranges
from 4% to 10% among persons diagnosed with diabetes
[6]. This translates to an annual population-based inci-
dence of 1.0% to 4.1% and a lifetime incidence as high as
25% [6].
At least 15% of people with diabetes will eventually
develop a lower-extremity ulcer of some sort [7]. Foot
deformities and limited joint mobility impose excessive
pressure on the plantar portion of the foot. This limitation
in joint mobility is secondary to non-enzymatic glycosyla-
tion of the periarticular soft tissues, and it reduces the
foot's ability to accommodate for ambulatory ground
reactive force to increase plantar pressure [8-13]. This
excessive pressure, combined with the repetitive or con-
stant stress from daily ambulation along with neuropathy,
will ultimately lead to failure of the protective integument
and ulceration. Although the precise pathophysiological
mechanism underlying the development of diabetic foot
ulcerations is complex [13], it is generally associated with
the presence of peripheral neuropathy and repetitive
trauma due to normal walking activities which expose the
foot to moderate or high pressure and shear forces [14-
16]. Brand [17] theorized that a local inflammatory
response, focal tissue ischemia, tissue destruction and
ulceration may occur when these types of forces are
applied to a specific area over an extended period of time.
Ulceration sites correlate with the highest plantar pressure
points [18-22]. By definition, these ulcers present within
the context of arterial perfusion adequate for wound heal-
ing [23]. The current standard treatment for foot ulcers
consists of debridement, treatment of infection, pressure
relief and arterial revascularization, if required [24].
The main objective of the present study was to evaluate
the healing rates of diabetic foot ulcers during a 20-week
period in patients treated with ESWT (plus standard ther-
apy), compared with standard therapy consisting of deb-
ridement and Silvercell dressing.
Methods
This study is a randomized, prospected, controlled, clini-
cal trial. A total of 30 patients were recruited from the Dia-
betic Ambulatory of Endocrinology Unit of the University
of Bari (Italy) between October 1, 2006 and March 31,
2007. Study subjects were evaluated for a total of 20
weeks.
Inclusion criteria were neuropathic foot plantar ulceration
below the malleoli for a period of at least 6 months with
an area wider than 1 cm2, age 30–70 years, a diameter of
the lesion between 0.5 and 5 cm and type 1 diabetes mel-
litus with insulin treatment for at least 5 years prior.
Patients also should have had peripheral neuropathy, as
defined by insensitivity to a 10-g monofilament and by a
vibration perception threshold measured at the malleolus
of at least 25 volts [25]. The vascular assessment consisted
of an ankle-brachial index > 0.7 and palpation of the dor-
salis pedis and posterior tibial arteries. If one or both arte-
rial pulses were not palpable, the subject was excluded.
Exclusion criteria included patients with any of the fol-
lowing around the time of ESWT applications: peripheral
vascular disease, coronary bypass, pregnancy, coagulation
diseases or history of neoplasia or other conditions, based
on the principal investigator's clinical judgment.
The population was randomized into two groups that
received standard care consisting of therapeutic footwear,
debridement and dressing. In addition to the standard
therapy, the ESWT group also received three applications
of shock wave therapy.
The study protocol and informed consent were approved
by the Ethics Committee of the University of Medicine in
Bari (Italy). Usual clinical management for neuropathic
ulcers was used, that is a regular debridement to remove
surrounding callus and local would care by Silvercell
dressing for an average of 48–72 hours. Then, in the ESWT
group, the shock wave applicator head was placed over the
wound, utilizing ultrasonic gel and plastic draping to pre-
vent any cross-contamination of the device.
The treatment lasted just one or two minutes. The proto-
col consisted of a course of three sessions (every 72
hours), with 100 pulses per 1 cm2 of wound delivered at
each session at a flux density of 0.03 mJ/mm2 using a elec-
tromagnetic lithotripter (MINILITH SL1 by STORZ MED-
ICAL) with a cylindrical coil, parabolic focus and
ultrasound scanning. We aimed the device directly around
the perimeter of the ulcer. The most the patient may have
noticed was the sound of the ESWT machine as it gener-
ates the shock wave, so no local anesthetic was used dur-
ing treatment.
Patients in the control group were treated with the essen-
tials of foot ulcer care, namely debridement, adequateBMC Musculoskeletal Disorders 2009, 10:54 http://www.biomedcentral.com/1471-2474/10/54
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pressure relief and treatment of infection, as required by
current international guidelines [24].
Patients were permitted to ambulate as tolerated, and
each patient was provided with an orthopedic device to
remove mechanical stress and pressure at the site of the
ulcer during walking.
The ulcers were photographed by digital camera using the
macro function. The wound area and its following reduc-
tions were measured with the Rhinoceros program run-
ning on a personal computer.
If clinical signs of infection were evident, a swab for bac-
teriological analysis was taken, and the microbiological
results were recorded. Wound infection was treated by
appropriate systemic antibiotics.
All data elements recorded during the study period were
entered and validated in Microsoft Excel. The time to com-
plete ulcer healing was measured as the number of days
from the start of treatment to the date in which each
patient achieved complete wound healing. If the healing
did not occur within the 20 weeks of the study, the patient
was considered to be non-healing and the time was not
registered. The comparison between the two treatment
groups was made as the proportion of patients (%) who
reached target healing of their ulcers at the end of the
study. The time to complete healing and the index of re-
epithelization of the wound area were compared between
the two groups. All data were expressed as mean ± SD and
analyzed by Student's t-test. P value less than 0.05 was
regarded as significant.
Results
There were no significant differences between the two
groups in terms of demographics and clinical data, as
reported in tables 1 and 2. Group A (treated with ESWT)
was composed of fifteen patients: nine males and six
females. The age of these patients was 56.2 +/- 4.9 (mean
+/- DS). Group B (treated with standard management)
was composed of fifteen patients: seven males and eight
females. The age of all the patients was 56.8 +/- 7.5 (mean
+/- DS). The median size of the lesion in group A was
297.8 +/- 129.4 mm2 (mean +/- DS) and in group B was
245 +/- 100.9 mm2 (mean +/- DS).
All patients of both groups completed the study and
attended all control visits. No significant differences
emerged between the two groups with regard to treatment
complications.
The proportions of ulcers that healed in 20 weeks in the A
and B groups were 53.33% and 33.33%, respectively.
For the ulcers that healed during the 20-week period, the
healing times were 60.8 +/- 4.7 days (mean +/- DS) in
group A and 82.2 +/- 4.7 days (mean +/- DS) in group B
patients (p < 0.001).
A significant difference was observed in the index of the
re-epithelization between the two groups, with values of
2.97 +/- 0.34 mm2/die (mean +/- DS) in the ESWT group
[fig. 1 and 2] and 1.30 +/- 0.26 mm2/die (mean +/- DS) in
the control-group (fig. 3 and 4) (p < 0.001). Both the heal-
ing rate and the healing time were increased in the ESWT
group, and the differences were statistically significant.
One patient in each group developed local signs of infec-
tion (peri-lesional erythema and edema), which led to the
administration of oral antibiotics (1 g b.i.d. amoxicillin-
clavulanate) for 10 days. The signs of infection were
resolved in five days in the one patient in the ESWT group
and in one week in the patient in the control group, and
both patients remained in the study.
Table 1: Characteristics of patients in the ESWT group (group A)
Patient Age Initial area (mm2) Complete healing (mm2) Re-epithelization index (mm2/die)
1. woman 47 185 60 3.1
2. man 50 390 - 2.7
3. man 66 440 - 3
4. woman 55 180 62 2.9
5. man 61 205 66 3.1
6. man 50 400 - 2.7
7. man 58 145 60 2.4
8. woman 62 450 - 2.9
9. woman 53 175 52 3.4
10. woman 56 180 66 2.7
11. man 55 460 - 3.2
12. man 56 215 57 3.8
13. man 58 375 - 2.6
14. man 57 187 64 2.9
15. woman 60 480 - 3.2BMC Musculoskeletal Disorders 2009, 10:54 http://www.biomedcentral.com/1471-2474/10/54
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Discussion
Neuropathic foot ulcers generally do not respond well to
treatment, and several novel treatment modalities have
been proposed over the past few years [26-29], including
the development of new dressings, growth factors, bioen-
gineered skin and tissue substitutes, hyperbaric oxygen,
negative pressure wound therapy and other novel
approaches to stimulate wound healing [30,29,31-33].
Limbs with non-healing neuropathic ulcers may eventu-
ally require amputation. Individuals with lower-limb
amputations are at risk for developing concomitant med-
ical ailments, report a diminished quality of life and are
more likely to die than other individuals with diabetes
[34]. In a meta-analysis of standard ulcer treatment, only
30% of individuals with a neuropathic diabetic foot ulcer
will heal within 20 weeks of commencing good care [35].
For the past 20 years, ESWT has been used in the treat-
ment of a number of musculoskeletal conditions, includ-
ing plantar fasciitis, tendinosis calcarea of the shoulder,
tennis elbow, pseudoarthrosis and algodystrophy. A
shock wave (SW) is a longitudinal acoustic wave, travel-
ling with ultrasonic speed in the water of the body tissue,
which is a single pressure pulse with a short needle-like
positive spike of less than 1 microsecond with a lower
amplitude [36]. SWs are known to exert "cavitation
effects" (a micrometer sized violent collapse of bubbles
inside the cells) and have recently been demonstrated to
induce localized impulses on cell membranes that resem-
ble shear stress [36,37]. The rational of this treatment is
the stimulation of tissue healing, reduction of calcifica-
tion and inhibition of pain receptors or denervation to
achieve pain relief [38-40].
Table 2: Characteristics of patients in the control group (group B).
Patient Age Initial area (mm2) Complete healing (mm2) Re-epithelization index (mm2/die)
1. man 45 440 - 1.3
2. man 55 145 80 1.8
3. man 43 300 - 1.5
4. woman 58 145 90 1.6
5. woman 63 250 - 1.3
6. man 59 275 - 1.2
7. woman 57 290 - 1.1
8. woman 68 350 - 0.7
9. man 52 100 83 1.2
10. woman 63 300 - 1.4
11. woman 65 105 80 1.3
12. man 59 310 - 1
13. woman 52 250 - 1.4
14. man 48 116 78 1.5
15. woman 65 300 - 1.2
The ulcer of case 9 in group A Figure 1
The ulcer of case 9 in group A. The lesion was localized 
to the plantar surface of the 3rd intermetatarsal space and 
was 175 mm2 before ESWT.
Ulcer of case 9 in group A Figure 2
Ulcer of case 9 in group A. The lesion healed after 52 
days with a re-epithelization index of 3.4 mm2/die.BMC Musculoskeletal Disorders 2009, 10:54 http://www.biomedcentral.com/1471-2474/10/54
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Researchers have shown that the local delivery of shock
wave therapy stimulates the early expression of angiogen-
esis-related growth factors, including endothelial nitric
oxide synthase, vascular endothelial growth factor and
proliferating cell nuclear antigen. As such, it results in new
vessel in-growth that improves blood supply, increases
cell proliferation and accelerates tissue regeneration and
healing [41,42]. A study of ESWT application on the por-
cine heart indicates that low-energy ameliorates myocar-
dial perfusion and cardiac function in a model of chronic
myocardial ischemia, and clinical trials started in patients
with severe chronic artery disease and no adverse effects
were found [43,44]. Recently, this treatment has also been
applied to skin lesions. In a previous study [45], treatment
with ESW was demonstrated to enhance epigastric skin
flap survival in rats, as confirmed by the significant reduc-
tion in necrotic flap zones. Additionally, in tissue samples
adjacent to the necrosis areas, increased vascular endothe-
lial growth factor expression was observed in the ESW-
treated skin flap [46]. Histological staining indicated that
ESW treatment substantially increased vascular endothe-
lial growth factor and proliferating cell nuclear antigen
expression, reduced leukocyte infiltration and suppressed
tumor necrosis factor alpha expression in flap tissue
ischemic zones compared with controls. It was postulated
that ESW treatment has a positive effect in rescuing the
ischemic zone of flaps by increasing tissue perfusion, and
it is associated with a suppression of the inflammatory
response [47]. After experimental studies in animal mod-
els, the clinical application of shock waves for the therapy
of acute and chronic soft tissue wounds is becoming more
popular. Two hundred and eight patients were prospec-
tively enrolled into a trial, and the treatment consisted of
debridement and ESWT at 100 to 1,000 shocks/cm2 at 0.1
mJ/mm2. Since surface defects are often involved,
researchers modified the shock wave head so that the
shock wave would no longer be focused in a small plane
of the treatment area. It was found that 75% of treated
patients had 100% wound epithelization during a 3 to 12
week period of monitoring [48].
Here we have completed a clinical trial to evaluate the
possibility of utilizing this treatment for wounds that have
a difficult recovery. We used an electromagnetic generator,
which we apply in the treatment of the orthopedic dis-
eases (fig. 5). We selected patients affected by diabetic
neuropathic foot ulcers. In a detailed analysis by Margolis
et al [35], of the factors that may contribute to healing, the
only ones that emerged from logistic regression were ulcer
area, ulcer duration and the race of the patient. This study
revealed that those patients with a diabetic neuropathic
foot ulcer that healed within 20 weeks using standard care
were more likely to have a smaller wound that existed for
a shorter period and to be non-whites, compared with
patients whose wounds did not heal within 20 weeks. The
neuropathic ulcers we studies were present for a longer
time prior to treatment, became larger and took more
time to heal. The patient's age, serum level of glycosylated
hemoglobin at the start and sex were not associated with
the probability of wound healing. Nevertheless, no differ-
ence was observed in the rate of healing of plantar and
non-plantar ulcers. In the meta-analysis, only 30.9% of
the diabetic neuropathic ulcers healed after 20 weeks of
good treatment [35].
During our previous preliminary experience in the appli-
cation of the shock waves for the treatment of ulcers, we
found that the rate of re-epithelization was higher in big
ulcers. To avoid any selection bias, we chose a homogene-
ous type of ulcer that was smaller than 5 cm in diameter
and of non-recent arising, both plantar and dorsal and in
Caucasian patients. In according with Ethic Committee's
Ulcer of case 4 in group B Figure 3
Ulcer of case 4 in group B. The lesion was localized to the 
plantar surface of the tarsus and was 145 mm2 before stand-
ard management.
Ulcer of case 4 in group B Figure 4
Ulcer of case 4 in group B. The lesion healed after 90 
days with a re-epithelization index of 1.6 mm2/die.BMC Musculoskeletal Disorders 2009, 10:54 http://www.biomedcentral.com/1471-2474/10/54
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indications, we ensured an advanced dressing in the man-
agement of the ulcers. Silvercell satisfied the need of anti-
microbial action and of exudates management in all the
ulcers of the study.
Our trial is the first randomized, controlled clinical study
on shock wave therapy for diabetic foot ulcers, and it
shows promising results for the application of ESWT [fig.
5]. Statistically significant differences were demonstrated
in the index of re-epithelization. It provides evidence that
ESWT doubles the mean healing index of re-epithelization
in diabetic, non-ischemic, chronic foot ulcers. In addition,
it suggests the possibility of shortening the time of heal-
ing.
In our two cases of infection we observed a rapid resolu-
tion in the SW group. The observed antibacterial effects of
the extracorporeal shockwaves could be highly relevant
for the treatment of non-healing wounds, which are com-
monly at increased risk of infection [49].
The rationale for the use of ESWT as an adjunctive treat-
ment for the diabetic foot arises from its beneficial effects
on the microenvironment of the wound. It stimulates
physiological angiogenesis, due to the release of NO and
vascular growth factors at the site of the ulcer. Recent
results suggest that SW therapy could be effective and safe
for the treatment of peripheral artery disease [50]. In a
rabbit hindlimb ischemia model, the development of col-
lateral arteries, the flow ratio of the ischemic/non-
ischemic common iliac arteries, the blood pressure ratio
of the ischemic/non-ischemic hindlimb and the capillary
density in the ischemic muscles were all significantly
increased in the SW group at three weeks after therapy
compared with the control group. These results indicate
that the SW therapy induced therapeutic angiogenesis.
Importantly, no adverse effects, such as muscle damage,
hemorrhage or thrombosis, were noted with the therapy,
and the expression levels of eNOS and VEGF proteins
tended to be increased.
We administrated the shockwaves every 72 hours for 3
sessions. We chose this protocol on the basis of our clini-
cal experience in Orthopedics treatment. Recently, the
International Society for Medical Shockwaves Treatment
published the "New guidelines for ESWT" and it suggested
to apply from 1 to 6 sessions, using an interval of 1 week
[51]. However, in literature good results of angiogenesis
are reported using different protocols in which the inter-
val between each session of shock waves varies from 48
hours to two weeks [43,52]. Following studies should be
useful for compare the effects of protocols which should
be different only for the interval time between each treat-
ment or for the dosage of shock waves.
ESWT seems effective in accelerating the healing rate of
non-ischemic chronic diabetic foot ulcers. Our new
results reinforce the interest in applying ESWT to ulcers
associated with neuropathy and macroangiopathy. On
the basis of these results, we can hypothesize that ESWT
should also be valid for arteriogenic ulcers, and we are
planning a new clinical trial to evaluate the effects of
ESWT on this type of ulcer.
The steps of ultrasonic gel, plastic draping and shock wave administration at work in the study Figure 5
The steps of ultrasonic gel, plastic draping and shock wave administration at work in the study.BMC Musculoskeletal Disorders 2009, 10:54 http://www.biomedcentral.com/1471-2474/10/54
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Conclusion
The present study assessed the safety and efficacy of shock
waves for the treatment of diabetic ulcers. There is a high
occurrence of foot ulcers within the population of diabet-
ics. Foot ulcerations may lead to lower extremity amputa-
tions and are major causes of disability to patients, often
resulting in significant morbidity, extensive periods of
hospitalization and mortality. In order to diminish the
detrimental consequences associated with diabetic foot
ulcers, a high standard of care must be provided. In the
present study, we have shown that the complete wound
healing rate was significantly increased in ESWT-treated
patients when compared with patients treated with the
standard state of the art care available at present. This was
accompanied by a significant reduction in the median
time required to heal the ulcer with no increase in the rate
of adverse reactions.
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